Ischemia‐induced Netrin‐4 promotes neovascularization through endothelial progenitor cell activation via Unc‐5 Netrin receptor B. Issue 1 (29th November 2019)

• Record Type: Journal Article
• Authors: Lee, Na Geum; Jeung, In Cheul; Heo, Soon Chul; Song, Jinhoi; Kim, Wooil; Hwang, Byungtae; Kwon, Min‐Gi; Kim, Yeon‐Gu; Lee, Jangwook; Park, Jong‐Gil; Shin, Min‐Gyeong; Cho, Young‐Lai; Son, Mi‐Young; Bae, Kwang‐Hee; Lee, Sang‐Hyun; Kim, Jae Ho; Min, Jeong‐Ki
• Is Part Of: FASEB journal. Volume 34:Issue 1(2020)
• Page Start: 1231
• Page End: 1246
• Publication Date: 2019-11-29
• Subjects: angiogenesis‐dependent diseases -- endothelial progenitor cells -- EPC‐based therapy -- neovascularization -- Netrin‐4; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.201900866RR
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract: Endothelial progenitor cells (EPCs) promote neovascularization and tissue repair by migrating to vascular injury sites; therefore, factors that enhance EPC homing to damaged tissues are of interest. Here, we provide evidence of the prominent role of the Netrin‐4 (NTN4)–Unc‐5 Netrin receptor B (UNC5B) axis in EPC‐specific promotion of ischemic neovascularization. Our results showed that NTN4 promoted the proliferation, chemotactic migration, and paracrine effects of small EPCs (SEPCs) and significantly increased the incorporation of large EPCs (LEPCs) into tubule networks. Additionally, NTN4 prominently augmented neovascularization in mice with hindlimb ischemia by increasing the homing of exogenously transplanted EPCs to the ischemic limb and incorporating EPCs into vessels. Moreover, silencing of UNC5B, an NTN4 receptor, abrogated the NTN4‐induced cellular activities of SEPCs in vitro and blood‐flow recovery and neovascularization in vivo in ischemic muscle by reducing EPC homing and incorporation. These findings suggest NTN4 as an EPC‐based therapy for treating angiogenesis‐dependent diseases.